Technical Data Sheet

InVivoSIM anti-human BCMA (Belantamab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0056**
Clone:	**Belantamab**
Isotype:	Human IgG1, κ
Recommended Isotype Control(s):	RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Mutations:	E356D/M358L
Immunogen:	Human BCMA (CD269)
Reported Applications:	*in vivo* functional assays *in vitro* functional assays Flow cytometry Immunoprecipitation Western blot ELISA
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Belantamab, making it ideal for research use. Belantamab is a humanized IgG1 monoclonal antibody that reacts with B-cell maturation antigen

(BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17). BCMA is a single-pass type III membrane glycoprotein, and it is selectively expressed by mature or differentiated plasma B-cells in normal lymphoid tissues (e.g., bone marrow, spleen, lymph nodes, and tonsils). BCMA is not expressed on naive B cells, T cells, monocytes/macrophages, neutrophils, and other normal tissues. BCMA is expressed uniformly and in high abundance in multiple myeloma tissues, and its low-to-moderate levels of expression are reported in several other hematologic malignancies also (e.g., chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, and non-Hodgkin/Hodgkin lymphomas). BCMA acts as a receptor for two distinct agonist ligands: B cell-activating factor [BAFF (also known as TNFSF13B or BLyS)] and a proliferation-inducing ligand (APRIL, also called TNFSF13). In comparison to BAFF/Blys, BCMA binds APRIL/TNFSF13 with higher affinity. BCMA plays a critical role in promoting B-cell survival and the regulation of humoral immunity. BCMA is also involved in the activation of NF-kappa-B and JNK-3 signaling pathways. In multiple myeloma, BCMA expression is directly related to the growth/proliferation of cancer cells, and serum levels of soluble BCMA (sBCMA) are suggested as a potential biomarker in multiple myeloma. In several experimental studies, an antibody-drug conjugate (ADC) consisting of belantamab conjugated to mafodotin has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and apoptosis in cancer cells.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information


Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0056?bxcs=9k1b3a#tab_references or scan the QR code below.

Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC